Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MW11 in Advanced Solid Tumors
NCT04478461Phase 1Unknown
- Sponsor
- Mabwell
- Start
- Sep 2020
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of recombinant humanized anti-PD-1 monoclonal antibody in solid tumor, sponsored by Mabwell. Primary endpoints: Adverse Event (AE) at 2 years and Severity Adverse Event at 2 years. Status: unknown.
02
Drugs
recombinant humanized anti-PD-1 monoclonal antibody
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04478461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04478461.